Welcome to our dedicated page for Nanoviricides news (Ticker: NNVC), a resource for investors and traders seeking the latest updates and insights on Nanoviricides stock.
NanoViricides, Inc. (NNVC) generates frequent news as a clinical stage biotechnology company focused on nanomedicine-based antiviral drug candidates. Its updates center on the development and regulatory progress of NV-387, a broad-spectrum antiviral that the company states is designed to mimic host cell attachment receptors such as sulfated proteoglycans, aiming to trap and neutralize a wide range of human pathogenic viruses.
News coverage for NanoViricides often highlights clinical and regulatory milestones. Recent announcements include approval by the regulatory agency ACOREP in the Democratic Republic of Congo to start a Phase II clinical trial of NV-387 for MPox, ongoing work toward a Phase II trial for viral acute and severe acute respiratory infections (viral ARI/SARI), and preparations for orphan drug designation applications for MPox, Smallpox, and Measles. The company also reports on its Phase I safety results for NV-387 and describes its efforts to advance NV-387 into Phase II human clinical trials.
Investors and observers following NNVC news can expect detailed discussions of preclinical and clinical data in animal models and early human studies, including comparisons of NV-387 to existing antivirals such as oseltamivir, baloxavir, peramivir, remdesivir, and tecovirimat. Press releases frequently address emerging viral threats, such as influenza A/H3N2 variants, H5N1 bird flu, MPox clades, coronaviruses, RSV, and Measles, and position NV-387 within these contexts.
NanoViricides also issues news on financing events, such as registered direct offerings and concurrent private placements, which support its research and development plans. Additional coverage includes presentations at investor and partnering conferences, shareholder meeting announcements, and commentary from company leadership on the potential role of nanoviricide technology in pandemic preparedness and bioterrorism response. Bookmark this page to review ongoing NNVC news as the company reports new data, regulatory interactions, and corporate developments.
NanoViricides (NYSE:NNVC) highlighted the need for broad‑spectrum antivirals amid a moderately severe 2025–26 influenza season driven by an H3N2 K subclade. CDC estimates cited include 15,000,000 illnesses, 180,000 hospitalizations, and 7,400 deaths as of January 6, 2026. The company positions its Phase II candidate NV-387 as a broad‑spectrum antiviral that targets virus binding to heparan sulfate and is active in animal models versus influenza A/H3N2, RSV and coronaviruses. NV-387 is claimed superior to oseltamivir and baloxavir in animal studies and produced a complete cure in an RSV model. NanoViricides says NV-387 could address a >$20 billion market if approved and is planning a Phase II trial for empiric treatment of respiratory viral infections.
NanoViricides (NYSE:NNVC) signed a Master Services Agreement on December 1, 2025 with Only Orphans Cote to develop an orphan drug regulatory strategy and prosecute orphan designation applications for NV-387 at the US FDA.
NV-387 has shown in vivo activity in lethal mouse orthopoxvirus (ectromelia) models and in a humanized animal measles model, and the company is focused on advancing NV-387 toward Phase II human trials. The release cites potential orphan incentives including tax credits, user-fee exemptions, and seven years of market exclusivity if approved. As of November 25, 2025, the release reports 1,798 confirmed US measles cases across 42 states.
NanoViricides (NYSE Amer.: NNVC) filed its Form 10-Q for the quarter ended September 30, 2025 and reported clinical and financing updates for its lead candidate NV-387.
Key financials as of 9/30/2025: $1.25M cash, $8.36M total assets (including $6.78M net P&E), and $1.18M current liabilities. Net cash used in Q3 was $1.59M.
Subsequent financings raised ~$6.1M (cash added as of 11/12/2025), including a $5.5M registered direct/private placement on 11/10/2025, plus ATM proceeds and a $3M founder line of credit. Company states runway is not sufficient to fund operations through Feb 14, 2026 without additional financing.
NanoViricides (NYSE American:NNVC) will present at the Pharma Partnering Summit 2025 in Boston on November 14, 2025 at 11:25 AM ET. The presentation by Anil R. Diwan will update the company, its drug pipeline and licensing opportunities.
The release highlights lead candidate NV-387, now in Phase II development and reported effective in animal models against Influenza A/H3N2, RSV, coronaviruses, MPox/smallpox and measles, and positioned for respiratory ARI/SARI indications.
NanoViricides (NYSE American: NNVC) closed a registered direct offering and concurrent private placement on November 12, 2025, raising approximately $6.0 million by selling 3,571,429 shares at $1.68 per share to a single healthcare institutional investor.
Concurrently, the company sold Series A warrants to purchase up to 3,571,429 shares at a $1.75 exercise price (exercisable after 6 months; 2-year term) and Series B warrants to purchase up to 3,571,429 shares at a $2.00 exercise price (exercisable after 6 months; 5.5-year term). Series B exercise price was ~20% premium to the Nov 10, 2025 closing price. Net proceeds will be used for working capital and general corporate purposes.
NanoViricides (NYSE American: NNVC) announced a registered direct offering of 3,571,429 shares at $1.68 per share for gross proceeds of approximately $6.0 million, expected to close on or about November 12, 2025, subject to customary conditions.
Concurrently the company will issue Series A warrants (exercise $1.75, exercisable after 6 months, 2‑year term) and Series B warrants (exercise $2.00, exercisable after 6 months, 5.5‑year term) to purchase up to 3,571,429 shares each. The Series B exercise price is ~20% premium to the Nov 10, 2025 closing price. Net proceeds are intended for working capital and general corporate purposes. A.G.P./Alliance Global Partners is sole placement agent.
NanoViricides (NYSE American: NNVC) announced on November 10, 2025 that the Democratic Republic of Congo regulatory agency ACOREP has approved the start of a Phase II clinical trial of NV-387 for treatment of MPox (hMPXV), subject to filing certain final documents and translations.
The company previously received Ethics Committee (CNES) clearance in May 2025 and is preparing English and French certified clinical trial application materials. NV-387 has reported broad preclinical antiviral activity across multiple lethal animal models, and the program targets MPox as well as other respiratory and systemic viral infections.
NanoViricides (NYSE:NNVC) will hold its Annual Shareholders Meeting on November 8, 2025 at 10:00 am at Hampton Inn & Suites Stamford, CT. Management will review progress toward clinical development, including completion of the Clinical Trial Application and plans to initiate a Phase II trial of NV-387 for MPox in the Democratic Republic of Congo. NV-387 completed a Phase I trial with a described safety and tolerability profile and showed efficacy in animal orthopoxvirus models versus tecovirimat.
The release also summarises MPox risks (recent US Clade I cases, case fatality ranges) and contrasts NV-387 with existing countermeasures and their limitations.
NanoViricides (NYSE American: NNVC) will present at the Spartan Capital Investor Conference in New York City on November 3, 2025 at 09:45am ET. Anil R. Diwan, PhD, President and Executive Chairman, will provide an update on the company, its drug pipeline and nanoviricide platform technologies available for licensing.
Key disclosed items include: NV-387 in Phase II (planned MPox trial in Democratic Republic of Congo) and development for RSV, influenza, COVID/Long COVID, and other respiratory indications; clinical-ready NV-HHV-1 (pan-herpesvirus) and NV-HIV-1; and platform capabilities for drug encapsulation, oral delivery, and targeted "zip-code" delivery. The release reiterates forward-looking risks and uncertainty about timelines, regulatory approvals, and development outcomes.
NanoViricides (NYSE American: NNVC) CEO Dr Anil Diwan told Proactive (Oct 29, 2025) that lead drug NV-387 showed potent anti-measles activity in cell culture and a humanized animal model and protected lung tissue.
In a lethal measles model, NV-387 extended survival by 130% (from 7.4 days to 17 days). NV-387 completed Phase I with no reportable adverse events and is formulated as oral gummies. The company said it can support emergency use or physician-initiated INDs and is advancing NV-387 into Phase II for MPox.
FAQ
What is the current stock price of Nanoviricides (NNVC)?
What is the market cap of Nanoviricides (NNVC)?
